Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

NCT04619004 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04619004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 2, 2021
Completion date
January 4, 2027
Enrollment
277 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic, non-small cell lung cancer with mutation in epidermal growth factor receptor